Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Feb 4 2022

2/4 – Jennifer J. Kang-Mieler, Illinois Institute of Technology

Biomedical Engineering Seminar

February 4, 2022

12:00 PM - 1:00 PM


Chicago, IL

Watch this seminar live here>>

Speaker: Jennifer J. Kang-Mieler, PhD, FARVO

Department of Biomedical Engineering
Pritzker Institute of Biomedical Science and Engineering
Illinois Institute of Technology

Title: Sustained Treatment with Anti-VEGF agents for Retinal diseases -Drug Delivery System (STAR-DDS)

Vascular Endothelial Growth Factor (VEGF) has been identified as a key regulator of angiogenesis both acting as an endothelial cell mitogen and increasing vascular permeability. Elevated VEGF concentrations have been correlated with multiple ocular diseases including age-related macular degeneration (AMD) with choroidal neovascularization (CNV) and diabetic retinopathy (DR). Landmark clinical studies demonstrated that anti-VEGF agent therapy (ranibizumab or aflibercept) was remarkably efficacious for AMD with CNV and DR; these drugs are now the gold standard treatment for these diseases. However, a major limitation for these treatments is that repeated dosing is required every four to six weeks. Frequent dosing is undesirable for a variety of reasons including: decrease patient comfort, increased likelihood of complications (e.g. endophthalmitis, retinal tears and detachment, intraocular hemorrhage, and cataract formation), and bolus administration of the agent. The repetitive treatment burden on the patients, family members, and clinicians is substantial. Consequently, there is a great need to develop a more effective, long-lasting, relatively non-invasive delivery method for anti-VEGF agents. My laboratory have created a Sustained Treatment with Anti-VEGF agents for Retinal diseases -Drug Delivery System (STAR-DDS) which utilizes biodegradable drug loaded- microspheres embedded into a biodegradable thermo-responsive hydrogel. The advantages of STAR-DDS are numerous and include easy injection into the vitreous via a small gauge needle. We have demonstrated that both ranibizumab and aflibercept can be released in a controlled manner for ~6 months. To our knowledge, STAR-DDS is the first system to demonstrate a sustained release of anti-VEGF for 6 months. This presentation will discuss the STAR-DDS and safety and efficacy of STAR-DDS.


UIC Biomedical Engineering

Date posted

Jan 13, 2022

Date updated

Jan 13, 2022